M&A Deal Summary

Innoviva Acquires Entasis Therapeutics

On May 23, 2022, Innoviva acquired life science company Entasis Therapeutics for 113M USD

Acquisition Highlights
  • This is Innoviva’s 1st transaction in the Life Science sector.
  • This is Innoviva’s 2nd largest (disclosed) transaction.
  • This is Innoviva’s 1st transaction in the United States.
  • This is Innoviva’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2022-05-23
Target Entasis Therapeutics
Sector Life Science
Buyer(s) Innoviva
Deal Type Add-on Acquisition
Deal Value 113M USD
Advisor(s) MTS Health Partners LP (Financial)
Covington & Burling LLP (Legal)

Target

Entasis Therapeutics

Waltham, Massachusetts, United States
website
Entasis Therapeutics is an advanced late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted antibacterial products that address high unmet medical needs to treat serious infections caused by multidrug-resistant pathogens. Entasis Therapeutics was founded in 2015 and is based in Waltham, Massachusetts.

Search 192,510 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Innoviva

Burlingame, California, United States

website

Category Company
Founded 1996
Sector Life Science
Employees101
Revenue 331M USD (2022)
DESCRIPTION

Innoviva is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development, and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Innoviva was founded in 1996 and is based in Burlingame, California.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 2
State (Massachusetts) 1 of 2
Country (United States) 1 of 2
Year (2022) 1 of 2
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-06-02 Theravance Biopharma

George Town, Cayman Islands

Theravance Biopharma is a biopharmaceutical company with one approved product, VIBATIV® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance Biopharma was founded in 2013 and is based in George Town, Caymen Islands.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-07-11 La Jolla Pharmaceutical

Waltham, Massachusetts, United States

La Jolla Pharmaceutical is a biotechnology company involved in the development of therapeutics for lupus nephritis and other autoimmune diseases. La Jolla Pharmaceutical was founded in 1989 and is based in Waltham, Massachusetts.

Buy $149M
Mergr

Product

Company

Legal